Highbridge Capital Management LLC acquired a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 214,545 shares of the company’s stock, valued at approximately $1,184,000. Highbridge Capital Management LLC owned about 0.79% of TriSalus Life Sciences at the end of the most recent quarter.
Separately, Wolverine Asset Management LLC purchased a new position in shares of TriSalus Life Sciences during the 2nd quarter worth $240,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.
TriSalus Life Sciences Trading Down 0.9 %
Shares of TLSI stock opened at $4.62 on Thursday. The stock has a fifty day simple moving average of $5.44 and a two-hundred day simple moving average of $7.37. TriSalus Life Sciences, Inc. has a 52-week low of $3.32 and a 52-week high of $10.42.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the company. Canaccord Genuity Group restated a “buy” rating and issued a $12.00 price objective on shares of TriSalus Life Sciences in a research note on Thursday, June 27th. Oppenheimer started coverage on TriSalus Life Sciences in a research note on Monday. They issued an “outperform” rating and a $10.00 price objective on the stock. Finally, Canaccord Genuity Group started coverage on TriSalus Life Sciences in a research note on Thursday, May 30th. They set a “buy” rating and a $12.00 price objective for the company.
View Our Latest Stock Report on TriSalus Life Sciences
Insider Buying and Selling at TriSalus Life Sciences
In related news, CEO Mary T. Szela bought 7,520 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the transaction, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 76.20% of the company’s stock.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
See Also
- Five stocks we like better than TriSalus Life Sciences
- Investing in Commodities: What Are They? How to Invest in Them
- How Much Can You Make in Stocks in One Month?
- With Risk Tolerance, One Size Does Not Fit All
- This Is the Top Large-Cap Stock Insiders Are Buying
- 10 Best Airline Stocks to Buy
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Want to see what other hedge funds are holding TLSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Free Report).
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.